The HER2 testing conundrum

被引：44

作者：

Allison, Malorye

机构：

来源：

NATURE BIOTECHNOLOGY | 2010年 / 28卷 / 02期

关键词：

D O I：

10.1038/nbt0210-117

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Problems in interpreting diagnostic tests for HER2 may be compromising patient access to effective treatments. As new versions of therapies targeting HER2 work their way through clinical trials, will the situation get even murkier? Malorye Allison investigates.

引用

页码：117 / 119

页数：3

共 4 条

[1] Trastuzumab: A Picky Partner? [J].

McArthur, Heather L. ;

Hudis, Clifford A. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6311-6313

[2]

MCARTHUR HL, 2009, EUR CANCER ORG 15 34

[3]

Perez EA, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.09.3849

[4] Clinical Practice Patterns and Cost Effectiveness of Human Epidermal Growth Receptor 2 Testing Strategies in Breast Cancer Patients [J].

Phillips, Kathryn A. ;

Marshall, Deborah A. ;

Haas, Jennifer S. ;

Elkin, Elena B. ;

Liang, Su-Ying ;

Hassett, MichaelJ. ;

Ferrusi, Ilia ;

Brock, Jane E. ;

Van Bebber, Stephanie L. .

CANCER, 2009, 115 (22) :5166-5174

← 1 →